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COMMENTARY
Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid
leukemia of normal karyotype
Malin S. Nilsson a, Alexander Hallner a, Mats Brune b, Staffan Nilsson c,d, Fredrik B. Thorén a,
Anna Martner a, and Kristoffer Hellstrand a
aTIMM Laboratory, Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of
Gothenburg, Gothenburg, Sweden; bDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University
of Gothenburg, Gothenburg, Sweden; cDepartment of Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden;
dDepartment of Laboratory Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
ABSTRACT
Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk
of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results
of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype
aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily
beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of
patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at
further defining the mechanism of relapse prevention by HDC/IL-2.
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Acute myeloid leukemia (AML) is characterized by rapid clonal
expansion of immaturemyeloid cells in bonemarrow. After initial
rounds of chemotherapy (induction), a majority of patients attain
complete remission (CR), defined as less than 5% leukemic blasts
in the bone marrow along with the return of non-malignant
hematopoiesis. Ensuing courses of chemotherapy (consolidation)
aim at eliminating residual leukemia. However, approximately
60–70% of adult patients in first CR (CR1) experience relapse of
AML, 1 mostly within 2–3 years, with dismal prognosis for long-
term survival. The absence of strategies to prevent relapse in the
post-chemotherapy phase in non-transplanted patients is
a significant reason why the rate of 5-year survival in adult AML
is in the range of 25–30%.1
AML cells invariably carry somatic genetic aberrations that
may be grouped by chromosomal morphology into AML of
aberrant or normal karyotype. In approximately 55% of human
adult AML, the leukemic cells thus carry structurally or numeri-
cally aberrant chromosomes, including deletion or multiplication
of chromosomes or chromosome sections [e.g. −5, −7, +8, +21,
+22, del(5q), del(7q), del(9q)] or inverted/translocated chromo-
some arms or segments [e.g. t(8;21), t(9;11), t(15;17), inv(16)].
Normal karyotype AML, where the chromosomes of leukemic
cells are morphologically and numerically intact, comprises muta-
tions in e.g. NPM1, FLT3-ITD, CEBPA, DNMT3A, IDH1 and
IDH2 and constitutes approximately 45% of all adult AML. The
mere classification of AML into aberrant or normal karyotype
does not provide major prognostic information. Instead, there are
entities within these groups of gene aberrations that herald vari-
able prognosis. Relapse risk and/or survival are thus favorably
impacted by t(8;21), t(15;17) and inv(16) translocations alongwith
NPM1 or CEBPA mutations, whereas somatic mutations in, e.g.,
FLT3-ITD or deletions of chromosomes 5 or 7 are associated with
poorer prognosis.2,3
Aspects of lymphocyte function and phenotype have been
reported to impact on the risk of relapse in the post-
consolidation phase of AML, and several immunotherapies have
been developed aiming at reducing the relapse risk.4 These include
administration of antibodies against leukemia-associated antigens,
treatmentwith immunostimulatory cytokines, adoptive transfer of
anti-leukemic lymphocytes and vaccine strategies using dendritic
cells carrying leukemic antigens or fusedwith autologous leukemic
cells.4,5 Of these, only immunotherapy with histamine dihy-
drochloride and low-dose interleukin-2 (HDC/IL-2) has proven
efficacious in terms of relapse prevention in a randomized phase
III setting6 (reviewed in)4. Treatment with HDC/IL-2 aims at
targeting the formation of immunosuppressive reactive oxygen
species produced by the NOX2 enzyme of myeloid cells (HDC
component), while concomitantly activating and expanding popu-
lations of natural killer (NK) cells and T cells (IL-2 component).
These components act in synergy to promote NK and T cell
function and viability in vitro, and also synergize to reduce or
inhibit tumor growth in animal models in vivo7–9 (reviewed in)4.
Here we report the results of exploratory analyses of the clinical
efficacy of HDC/IL-2 in AML with focus on the impact of genetic
aberrations in leukemic cells. Our data suggest that HDC/IL-2 is
primarily beneficial for patients with AML of normal karyotype.
The analyses presented are founded on databases of a phase III
study6 and a phase IV trial10 using HDC/IL-2 for relapse preven-
tion in AML. In the phase III trial, 320 AML patients in CR who
had completed consolidation chemotherapy were randomized to
treatment with HDC/IL-2 (n = 160) or standard of care (no
treatment; n = 160). Patients were median 57 (18–84) years at
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inclusion. Two-hundred sixty-one patients were in their first CR
(CR1), and 59 in their second or subsequent CR (CR>1). Patients
were recruited at 100 centers in Europe, USA, Australia and New
Zealand. Details of study procedures for random assignment,
exclusion criteria, dosing, treatment schedules and toxicity are
accounted for in a previous report.6 In brief, patients in the
treatment arm received up to ten cycles of HDC (0.5mg s.c. bid)
and low-dose IL-2 (16,400U/kg s.c bid) for 21 days followed by
21 days of rest. Beginning in cycle 4, the rest periods were
extended to 42 days. Treatment continued for up to 18 months,
and all surviving patients were followed for at least 36 months.
The primary trial endpoint was leukemia-free survival (LFS,
defined as the time from randomization to relapse or death
from any cause). Secondary endpoints included overall survival
(OS) and efficacy in terms of LFS andOS in subgroups such as CR
status (CR1 or CR>1 at randomization), age (<60 or ≥60 years)
and baseline characteristics including genetic aberrations in leu-
kemic cells.
The phase IV trial (Re:Mission Trial;10) was a single-armed
multicenter phase IV study that enrolled 84 patients (age 18–79,
median 61) with AML in CR1 who were not eligible for allogeneic
transplantation. All patients received HDC/IL-2 using a schedule
and dosing identical to that employed in the phase III trial. All
surviving patients were followed for at least 24 months after
enrollment. The endpoints included assessment of the quantita-
tive and qualitative pharmacodynamic properties of HDC/IL-2 on
immune populations, including T and NK cell phenotypes, as
analyzed before and after treatment cycles. Forty-four of the
patients in the phase IV trial harbored AML cells of normal
karyotype (age 28–74, median 60). Fifteen of the normal karyo-
type patients (age 28–74, median 60) carried leukemic cells with
NPM1mutations (out of 36 analyzed; 42%), whereas four patients
(age 53–64, median 64) carried FLT3-ITD mutations (out of 38
analyzed; 11%). Three of the latter patients carried mutations in
bothNPM1 and FLT3-ITD. Further patient characteristics includ-
ing previous induction and consolidation therapies and risk group
distribution are accounted for elsewhere.10,11 The phase III and
phase IV trials were approved by the Ethical Committees of each
participating institution and all patients gave written informed
consent before enrollment. The logrank test was applied to
Figure 1. Clinical efficacy of HDC/IL-2 in patients with aberrant or normal karyotype AML. Analysis of the impact of HDC/IL-2 treatment on leukemia-free
survival (LFS) and overall survival (OS) in a phase III trial. The Kaplan-Meier plots show LFS (a) or OS (b) in patients in CR1 with known karyotype (n = 225). Figures (c)
and (d) show corresponding results in patients with normal karyotype AML who were below or above 60 years old at random assignment. The logrank test was
employed for statistical analysis.
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analyze the impact of treatment with HDC/IL-2 on LFS andOS in
subgroups of patients harboring leukemic cells with normal or
aberrant karyotype as defined at diagnosis.
The potential efficacy of HDC/IL-2 was assessed in CR1
patients with normal or aberrant karyotype AML who partici-
pated in the randomized phase III trial. The karyotypic features
of leukemic cells were unknown in 36 of the 261 patients in
CR1. Thus, data obtained from 225 CR1 patients with known
karyotype were available for analysis of clinical outcome (LFS
and OS). There was no discernable treatment effect on outcome
(LFS or OS) among patients in CR1 with aberrant karyotype.
By contrast, HDC/IL-2-treated patients with normal karyotype
AML displayed improved LFS over control patients with
a trend towards improved OS (Figure 1a and b). HDC/IL-2
was not significantly efficacious in older patients with aberrant
or normal karyotype. Younger patients (<60 years) with nor-
mal karyotype AML showed significantly improved LFS and
OS vs. control patients (Figure 1c and d). These results imply
that the clinical benefit of HDC/IL-2 in AML is pronounced in
patients harboring leukemic cells of normal karyotype.
Mutations of NPM1 or FLT3-ITD are the most prevalent
mutations within the group of normal karyotype AML, where
mutated NPM1 comprises approximately 40–50% of cases and
FLT3-ITD approximately 30–40%.12 During the course of the
phase III trial, analyses of NPM1 and FLT3-ITD were not part of
clinical practice. However, in the ensuing single-armphase IV trial
using HDC/IL2 this information was available, and we thus ana-
lyzed outcome of patients with the two dominant mutations in
normal karyotype AML. The results did not support efficacy of
HDC/IL-2 in patients harboring mutated FLT3-ITD as 4/4
patients relapsed within 200 days. The outcome was, however, as
expected, more favorable in patients diagnosed with NPM1-
mutated AML devoid of karyotype aberrations or FLT3-ITD
mutations, where 67% of patients (n = 14) were alive and relapse-
free at 2 years.
In conclusion, the phase III trial results point to the possibility
that HDC/IL-2 is clinically efficacious in AML patients with
leukemic cells of normal but not aberrant karyotype, and that
this aspect of clinical efficacy is pronounced in younger patients.
The magnitude of efficacy of HDC/IL-2 in AML patients with
normal karyotype, in particular in patients <60 years, suggests
that the treatment effect is present within the groups of NPM1-
and/or FLT3-ITD-mutated AML, as these mutations account for
>75% of all normal karyotype AML.12 The results of the phase IV
trial argue against the possibility that HDC/IL-2 is beneficial in
patients with normal karyotype AML carrying FLT3-ITD-
mutations, thus raising the possibility that HDC/IL-2 may be
primarily efficacious in NPM1-mutated AML. The exploratory
nature of these results should be emphasized, and controlled
trials are warranted to determine the potential benefit of HDC/
IL-2 in defined genetic subgroups of normal karyotype AML.
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